Table 3 Characteristics of the 1:1 Propensity Score Matched (Sensitivity Analysis) Rivaroxaban and Warfarin Cohorts

 Age, median (25, 75% range)

50 (39, 62)

51 (40, 64)

–

 Age 18–49 years

46.32

48.21

0.04

 Age 50–64 years

30.03

30.32

0.01

 Age 65–74 years

13.10

12.28

0.03

 Age 75–79 years

4.59

3.77

0.04

 Age ≥ 80 years

5.95

5.42

0.02

 Female sex

56.19

55.66

0.01

 Pulmonary embolism (±deep vein thrombosis)

18.09

17.89

0.01

 Chronic obstructive pulmonary disease

8.37

7.98

0.01

 Asthma

13.25

13.10

0.00

 Heart Failure

4.84

4.93

0.00

 Hypertension

52.80

51.45

0.27

 Ischemic stroke or transient ischemic attack

2.95

2.85

0.01

 Diabetes

21.13

21.03

0.00

 Dementia

2.18

2.03

0.01

 Coronary artery disease

0.68

0.87

0.02

 Carotid stenosis

0.63

0.53

0.01

 Peripheral vascular disease

5.51

5.42

0.00

 Myocardial infarction

5.08

4.59

0.02

 Percutaneous coronary intervention

3.34

3.13

0.01

 Coronary artery bypass grafting

1.93

2.18

0.02

 Gastrointestinal bleed

0.24

0.29

0.01

 Intracranial hemorrhage

0.00

0.00

NA

 Acute kidney injury

10.06

9.38

0.02

 Other kidney injury

0.24

0.24

0.00

 Inflammatory bowel disease

0.77

0.82

0.01

 eGFR > 90 mL/minute

55.42

58.32

0.06

 eGFR 60–89 mL/minute

0.48

0.73

0.03

 eGFR 30-59 mL/minute

31.09

28.97

0.05

 eGFR 15–29 mL/minute

10.88

10.06

0.03

 eGFR < 15 mL/minute

1.21

1.11

0.01

 eGFR unknown

0.77

0.68

0.01

 Liver disease

1.50

1.93

0.03

 Coagulopathy

3.00

3.00

0.00

 Gastroesophageal reflux disease

18.76

18.96

0.00

 Anemia

24.13

23.55

0.01

 Sleep apnea

10.20

10.64

0.01

 Smoking

28.77

28.19

0.01

 Hemorrhoids

2.22

2.37

0.01

 Alcohol abuse

0.34

0.34

0.00

 Anxiety

12.28

14.02

0.05

 Depression

1.69

1.60

0.01

 Psychosis

1.50

1.16

0.03

 BMI < 18.5 kg/m²

1.60

1.74

0.01

 BMI 18.5–24.9 kg/m²

15.43

14.46

0.03

 BMI 25.0–29.9 kg/m²

24.71

25.29

0.01

 BMI 30.0–34.9 kg/m²

23.26

23.79

0.01

 BMI 35.0–39.9 kg/m²

14.70

15.47

0.02

 BMI ≥40 kg/m²

19.15

17.65

0.04

 BMI unknown

1.16

1.60

0.03

 Rheumatoid arthritis

5.80

6.53

0.03

 Osteoarthritis

18.86

18.23

0.02

 Headache

10.15

10.59

0.01

 Diverticulitis

3.72

3.77

0.00

 H. pylori treatment

0.39

0.34

0.01

 Hypothyroidism

0.87

0.87

0.00

 Solid tumor

9.72

8.90

0.03

 Metastatic cancer

3.72

3.29

0.02

 Major surgery

10.11

10.01

0.00

 Varicose veins

1.26

1.35

0.01

 Aspirin

22.10

21.47

0.02

 P2Y12 platelet inhibitor

2.90

2.80

0.01

 Nonsteroidal anti-inflammatory drug

31.33

33.95

0.05

 Celecoxib

1.02

1.35

0.03

 Angiotensin-converting enzyme inhibitor or receptor blocker

30.66

29.21

0.03

 Beta-blocker

22.44

21.52

0.02

 Diltiazem

1.55

1.69

0.01

 Verapamil

0.87

0.87

0.00

 Dihydropyridine calcium channel blocker

20.31

19.44

0.02

 Loop diuretic

10.69

9.91

0.03

 Thiazide

21.08

20.45

0.02

 Digoxin

0.44

0.39

0.01

 Statin

23.02

21.66

0.03

 Other cholesterol medication

2.13

1.98

0.01

 Metformin

11.41

11.17

0.01

 Sulfonylurea or glinides

4.64

4.30

0.02

 Thiazolidinediones

0.34

0.53

0.03

 Dipeptidyl peptidase 4 inhibitors

1.35

1.64

0.02

 Glucagon-like peptide-1 agonist

0.29

0.44

0.02

 Insulin

7.54

7.06

0.02

 Selective serotonin reuptake or serotonin-norepinephrine reuptake inhibitor

10.88

10.74

0.00

 Other antidepressants

8.95

8.80

0.01

 Proton pump inhibitors

21.23

21.03

0.00

 Histamin-2 receptor antagonist

9.14

8.46

0.02

 Systemic corticosteroids

18.13

18.09

0.00

 Alpha-glucosidase inhibitor

0.00

0.00

0.00

 Hypnotic medication

3.68

4.01

0.02

 Sodium-glucose cotransporter-2 inhibitor

0.15

0.19

0.01